Relapsing Remitting Multiple Sclerosis (RRMS) is an indication for drug development with over 50 pipeline drugs currently active. According to GlobalData, preregistered drugs for Relapsing Remitting Multiple Sclerosis (RRMS) have a 95.65% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Relapsing Remitting Multiple Sclerosis (RRMS) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Relapsing Remitting Multiple Sclerosis (RRMS) overview
Relapsing-remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis (MS), a chronic autoimmune condition that affects the central nervous system. In RRMS, individuals experience intermittent episodes of new or worsening symptoms (relapses or exacerbations) lasting days to weeks, followed by periods of partial or complete recovery (remission) with stable or improved function. Symptoms of RRMS can vary widely and may include fatigue, numbness or tingling, muscle weakness, vision problems, balance and coordination difficulties, cognitive changes, and problems with bladder or bowel function. The severity and specific symptoms can differ among individuals and can also vary over time. During the early stages of RRMS, most individuals experience relapses followed by remissions. Over time, some people may transition to a secondary progressive form of MS, where disability accumulates steadily, with or without relapses. The exact cause of RRMS is not fully understood, but it is believed to involve a complex interaction between genetic, environmental, and immunological factors. In MS, the immune system mistakenly attacks the protective myelin sheath surrounding nerve fibers in the brain and spinal cord, leading to nerve damage and disruption of nerve signals.
For a complete picture of PTSR and LoA scores for drugs in Relapsing Remitting Multiple Sclerosis (RRMS), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
